NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
36.29
Dollar change
+0.80
Percentage change
2.25
%
Index- P/E- EPS (ttm)-1.19 Insider Own1.44% Shs Outstand184.03M Perf Week5.80%
Market Cap6.68B Forward P/E55.64 EPS next Y0.65 Insider Trans0.00% Shs Float181.38M Perf Month25.35%
Enterprise Value6.04B PEG- EPS next Q-0.11 Inst Own46.74% Short Float7.92% Perf Quarter6.96%
Income-218.15M P/S9.17 EPS this Y13.38% Inst Trans-5.89% Short Ratio7.86 Perf Half Y10.71%
Sales728.30M P/B6.56 EPS next Y256.87% ROA-12.87% Short Interest14.37M Perf YTD11.52%
Book/sh5.53 P/C6.64 EPS next 5Y- ROE-20.00% 52W High60.87 -40.38% Perf Year-18.74%
Cash/sh5.46 P/FCF- EPS past 3/5Y30.35% 0.79% ROIC-15.86% 52W Low27.34 32.74% Perf 3Y-31.35%
Dividend Est.- EV/EBITDA- Sales past 3/5Y108.88% 61.40% Gross Margin62.38% Volatility5.01% 5.60% Perf 5Y-9.34%
Dividend TTM- EV/Sales8.29 EPS Y/Y TTM54.33% Oper. Margin-33.28% ATR (14)1.83 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.07 Sales Y/Y TTM112.46% Profit Margin-29.95% RSI (14)61.22 Recom1.20
Dividend Gr. 3/5Y- - Current Ratio5.20 EPS Q/Q-67.18% SMA205.20% Beta0.19 Target Price76.40
Payout- Debt/Eq0.36 Sales Q/Q107.52% SMA5011.51% Rel Volume1.01 Prev Close35.49
Employees2609 LT Debt/Eq0.35 EarningsMay 13 BMO SMA200-2.98% Avg Volume1.83M Price36.29
IPOJun 05, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-28.33% 0.73% Trades Volume1,854,331 Change2.25%
Date Action Analyst Rating Change Price Target Change
Oct-08-24Initiated Redburn Atlantic Buy $86
Jun-17-24Initiated Truist Buy $88
May-24-24Reiterated H.C. Wainwright Buy $86 → $73
May-23-24Initiated Deutsche Bank Buy $60
Apr-17-24Upgrade Scotiabank Sector Perform → Sector Outperform $65
Apr-03-24Initiated Cantor Fitzgerald Overweight $82
Mar-13-24Initiated Raymond James Outperform $86
Dec-19-23Initiated Scotiabank Sector Perform
Nov-06-23Initiated Goldman Buy $90.09
May-25-23Initiated William Blair Mkt Perform $64
Jun-20-25 04:08PM
Jun-03-25 10:45AM
May-22-25 05:15PM
May-19-25 08:00AM
May-14-25 09:18AM
03:06AM Loading…
03:06AM
12:24AM
May-13-25 07:00AM
May-12-25 09:20AM
May-03-25 04:51AM
May-02-25 12:00PM
09:55AM
Apr-29-25 08:00AM
Apr-24-25 06:53AM
Apr-16-25 09:53AM
12:30AM Loading…
Apr-11-25 12:30AM
Apr-09-25 05:53AM
Apr-01-25 11:50AM
Mar-12-25 03:02AM
01:34AM
Mar-11-25 09:30AM
07:00AM
Feb-25-25 08:00AM
Feb-23-25 01:29PM
Feb-21-25 09:43AM
Feb-20-25 12:18PM
Feb-13-25 02:06PM
Feb-08-25 09:29AM
Jan-30-25 05:01PM
Jan-17-25 11:04AM
08:01AM Loading…
Dec-19-24 08:01AM
Dec-11-24 07:22AM
Dec-09-24 07:35PM
04:22PM
Nov-27-24 10:02AM
Nov-22-24 07:31AM
Nov-21-24 05:28PM
Nov-13-24 03:28AM
02:07AM
Nov-12-24 09:30AM
07:00AM
Nov-11-24 09:55AM
07:04AM
Nov-07-24 07:30AM
Nov-05-24 09:10AM
Nov-04-24 07:30AM
Oct-24-24 09:55AM
08:00AM
Oct-16-24 03:45PM
Oct-03-24 07:30AM
Sep-30-24 04:11PM
09:46AM
Sep-27-24 04:35PM
04:30PM
Sep-24-24 09:00AM
Sep-14-24 07:22PM
Sep-12-24 03:34AM
Sep-03-24 12:01PM
Aug-27-24 10:28AM
Aug-20-24 08:00AM
Aug-09-24 07:00AM
Aug-08-24 04:05PM
Jul-29-24 03:24PM
Jul-26-24 07:00AM
Jul-15-24 09:17AM
07:39AM
Jul-10-24 08:00AM
Jul-02-24 08:00AM
Jun-24-24 08:13AM
Jun-20-24 05:26PM
Jun-03-24 04:00PM
May-29-24 08:00AM
May-23-24 05:00PM
May-15-24 08:19AM
May-14-24 09:23AM
06:54AM
03:01AM
12:20AM
May-13-24 11:53AM
09:24AM
08:57AM
07:30AM
07:00AM
May-09-24 08:52AM
Apr-25-24 11:28AM
Apr-22-24 01:37PM
01:05PM
Apr-11-24 08:00AM
Apr-08-24 08:48AM
Apr-05-24 11:36PM
11:30PM
Apr-03-24 05:39AM
Mar-29-24 05:09AM
Mar-19-24 08:30AM
Mar-17-24 08:50AM
Mar-15-24 03:15PM
Mar-12-24 08:20AM
Mar-11-24 07:00AM
Feb-23-24 07:15AM
Feb-13-24 08:00AM
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Casey Patrick JohnDirectorJun 26 '25Proposed Sale33.231,00033,234Jun 26 11:21 AM
Huang YingOfficerJun 25 '25Proposed Sale33.7212,119408,653Jun 25 10:31 AM
Huang YingOfficerJun 24 '25Proposed Sale34.6011,810408,600Jun 24 04:23 PM
Sanders Corazon (Corsee) D.DirectorJun 24 '25Proposed Sale34.3730710,552Jun 24 10:05 AM
Casey Patrick JohnDirectorJun 06 '25Proposed Sale32.321,00032,320Jun 06 11:18 AM
Huang YingOfficerMay 01 '25Proposed Sale34.556,548226,233May 01 11:06 AM
Yeung JessieOfficerMar 25 '25Proposed Sale35.2833911,959Mar 25 03:47 PM
Huang YingOfficerMar 25 '25Proposed Sale35.284,064143,371Mar 25 03:41 PM
Sanders Corazon (Corsee) D.DirectorMar 25 '25Proposed Sale36.3330711,153Mar 25 12:15 PM
Macomber LoriFormer OfficerMar 13 '25Proposed Sale37.5232,6321,224,285Mar 13 11:42 AM
Macomber LoriFormer OfficerJan 10 '25Proposed Sale32.192,25472,553Jan 10 03:14 PM
Huang YingOfficerDec 24 '24Proposed Sale32.4563,0612,046,512Dec 26 09:59 AM
Macomber LoriOfficerDec 24 '24Proposed Sale32.451896,134Dec 26 09:48 AM
Heyman Tomas J.DirectorDec 02 '24Proposed Sale43.314,366189,080Dec 02 03:08 PM
Huang YingOfficerSep 25 '24Proposed Sale44.101,50466,326Sep 25 03:30 PM
Macomber LoriOfficerSep 20 '24Proposed Sale48.9190,0604,405,003Sep 20 04:43 PM
Yau Wai Man PhilipDirectorSep 20 '24Proposed Sale51.041,94699,324Sep 20 10:46 AM